Servier shared a post on LinkedIn:
“In May 2025, we acquired a best-in-class precision therapy for acute leukemias from BioNova Pharmaceuticals. This innovative treatment will help us address critical needs in hematologic cancers and offer new solutions to patients.
Did you know? Acute myeloid leukemia (AML) affects five out of 100,000 people living in Europe and over 20,000 new cases of AML were diagnosed in 2024 in the USA.
Through this acquisition, we reinforce our commitment to developing targeted therapies and improving outcomes for patients with rare and severe conditions.
Proceed to the video attached to the post.
More posts about Servier.